ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "0ff72c84-6e5c-4ed7-9798-1a35eef22ac6"}, "_deposit": {"id": "24853", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "24853"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00024853", "sets": ["501"]}, "author_link": ["73920", "73921", "73922", "73923"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-08", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "307", "bibliographicPageStart": "304", "bibliographicVolumeNumber": "471", "bibliographic_titles": [{"bibliographic_title": "Clinica Chimica Acta", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Anti-Su antibodies are found in 5–20% of cases of various systemic autoimmune rheumatic diseases and in 5–10% of dermatomyositis (DM)/polymyositis (PM) patients. In 2006, the 100 kDa Su antigen was identified as argonaute2 (Ago2), and it was found to play a major role in RNA interference. However, immunoprecipitation (IP) remains the main method for detecting anti-Su and the clinical significance of the antibodies is uncertain. Methods: Sera from patients with DM/PM (n = 224) were screened by an ELISA that uses recombinant biotinylated Ago2 protein. Some serum samples were tested by IP and by indirect immunofluorescence (IIF) analysis. Results: Seventeen (7.5%, 17/224) sera from DM/PM were positive in ELISA. Of the 33 IP-tested sera (17 ELISApositive and 16 ELISA-negative with high background), 13 were found to be anti-Ago2/Su-positive in IP and ELISA. Only one IP-positive serum was judged to be ELISA-negative. Among the 13 patients with anti-Su/Ago2, 7 cases also had myositis-specific autoantibodies. Six sera that were positive by both IP and ELISA showed the GW body pattern in IIF. Interestingly, one ELISA-positive serum with an inconclusive result in IP also showed the GW body pattern. Conclusion: Our novel ELISA appears to be useful for screening anti-Su/Ago2 antibodies (sensitivity: 93%, specificity: 79%).", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.1016/j.cca.2017.06.022"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/27073"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.cca.2017.06.022", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0009-8981", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mariko, Ogawa-Momohara", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73920", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshinao, Muro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73921", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minoru, Satoh", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73922", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masashi, Akiyama", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73923", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-08-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CCA-D-17-00162R2_1.pdf", "filesize": [{"value": "372.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 372700.0, "url": {"label": "CCA-D-17-00162R2_1.pdf ファイル公開日:2018/08/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/24853/files/CCA-D-17-00162R2_1.pdf"}, "version_id": "7215c4d3-f7fc-49bb-a64a-cf269468e5e5"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/27073", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-11-07"}, "publish_date": "2017-11-07", "publish_status": "0", "recid": "24853", "relation": {}, "relation_version_is_last": true, "title": ["Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy

http://hdl.handle.net/2237/27073
http://hdl.handle.net/2237/27073
86febf11-c023-4cf8-9025-d47e602c2678
名前 / ファイル ライセンス アクション
CCA-D-17-00162R2_1.pdf CCA-D-17-00162R2_1.pdf ファイル公開日:2018/08/01 (372.7 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2017-11-07
タイトル
タイトル Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy
言語 en
著者 Mariko, Ogawa-Momohara

× Mariko, Ogawa-Momohara

WEKO 73920

en Mariko, Ogawa-Momohara

Search repository
Yoshinao, Muro

× Yoshinao, Muro

WEKO 73921

en Yoshinao, Muro

Search repository
Minoru, Satoh

× Minoru, Satoh

WEKO 73922

en Minoru, Satoh

Search repository
Masashi, Akiyama

× Masashi, Akiyama

WEKO 73923

en Masashi, Akiyama

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
言語 en
権利情報 © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
抄録
内容記述 Background: Anti-Su antibodies are found in 5–20% of cases of various systemic autoimmune rheumatic diseases and in 5–10% of dermatomyositis (DM)/polymyositis (PM) patients. In 2006, the 100 kDa Su antigen was identified as argonaute2 (Ago2), and it was found to play a major role in RNA interference. However, immunoprecipitation (IP) remains the main method for detecting anti-Su and the clinical significance of the antibodies is uncertain. Methods: Sera from patients with DM/PM (n = 224) were screened by an ELISA that uses recombinant biotinylated Ago2 protein. Some serum samples were tested by IP and by indirect immunofluorescence (IIF) analysis. Results: Seventeen (7.5%, 17/224) sera from DM/PM were positive in ELISA. Of the 33 IP-tested sera (17 ELISApositive and 16 ELISA-negative with high background), 13 were found to be anti-Ago2/Su-positive in IP and ELISA. Only one IP-positive serum was judged to be ELISA-negative. Among the 13 patients with anti-Su/Ago2, 7 cases also had myositis-specific autoantibodies. Six sera that were positive by both IP and ELISA showed the GW body pattern in IIF. Interestingly, one ELISA-positive serum with an inconclusive result in IP also showed the GW body pattern. Conclusion: Our novel ELISA appears to be useful for screening anti-Su/Ago2 antibodies (sensitivity: 93%, specificity: 79%).
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Elsevier
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 https://doi.org/10.1016/j.cca.2017.06.022
ISSN
収録物識別子タイプ PISSN
収録物識別子 0009-8981
書誌情報 en : Clinica Chimica Acta

巻 471, p. 304-307, 発行日 2017-08
著者版フラグ
値 author
URI
識別子 http://doi.org/10.1016/j.cca.2017.06.022
識別子タイプ DOI
URI
識別子 http://hdl.handle.net/2237/27073
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 13:51:46.143016
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3